Small Cap Feast
Small Cap Feast – 10 October 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Joiners Today
No Joiners Today
What’s Cooking in the IPO Kitchen?
Main Market premium
Registration document approved for Helios Towers. The Group provides essential network services, flexible infrastructure solutions and reliable power supply to mobile network operators in five African growth economies. Revenue increased 7 per cent. year-on-year to US$191m (H1 2018: US$178m), with Adjusted EBITDA up 15 per cent. year-on-year at US$99m (H1 2018: US$86m) for the six months ended 30 June 2019. Pricing rumoured at 115p to 145p implying valuation of up to $1.8bn. Expected Oct 2019.
Osirium Technologies (OSI) 34p £4.6m
Osirium Technologies, a leading vendor of cloud-based cybersecurity software, announced a series of contract wins with an international banking group, a leading drinks manufacturer, and a provider of services to the pharmaceutical and biotech sectors.
The total licenses cover 100s of devices, with contract terms of between 12 and 36 months, with Osirium delivering its PxM Platform including the Privileged Access Management, Privileged Task Management and Privileged Session Management modules.
For the banking group the PxM platform has been selected to secure access to web interfaces, network devices and servers, and to control access to privileged accounts by a number of the customer’s key external vendors. In addition to core privileged access management functions, the customer has selected Osirium’s award-winning Task Automation capabilities to enable its Helpdesk team achieve significant time savings and enhanced security by automating processes in its day to day operations.
Castleton Technology (CTP) 53p £76m
Castleton Technology , the software and managed services provider to the public and not-for-profit sectors, today announces the following update on trading for the six-month period to 30 September 2019. The Company generated revenue of not less than £11.6m, adjusted EBITDA* of not less than £2.9m and cash generation in the period of not less than 79% of adjusted EBITDA, facilitating a continued reduction in the Company’s net debt compared to the prior year.
Recurring revenue has increased on an absolute basis and represented approximately 65% of total revenue in the period.
Trading in HY2019 has been behind expectations, primarily due to product and professional services revenue being lower than anticipated. The increase in recurring revenue has not been enough to offset the reduction in one-off revenue, and as a result of this, revenue, EBITDA and operating cash are lower than the strong comparable period last year.
IQE (IQE) 62p £484m
IQE plc the leading supplier of advanced wafer products and material solutions to the semiconductor industry, announces the acquisition of third-party shareholdings in its CSDC joint venture in Singapore taking its ownership to 100%.
CSDC was formed in March 2015 as a joint venture between IQE’s Singaporean subsidiary MBE Technology Pte Limited (51%), WIN Semiconductors Corp (25%), Nanyang Technological University (18%) and individuals of the NanYang University (6%). It was established as a vehicle for the development and commercialisation of compound semiconductor technologies for academic and industrial customers based on Molecular Beam Epitaxy (MBE) technologies in Asia.
Since formation, the geo-political landscape has changed significantly. During 2019 in particular, the localisation of Asian technology supply chains is rapidly becoming evident and significant opportunities are emerging for the China 5G market.
Motif Bio PLC (MTFB) 0.6p £2.3m
Motif Bio announced that the Company has received the official minutes of the Type B meeting with the U.S. Food & Drug Administration (FDA) which took place on September 19, 2019.
As disclosed in the announcement on September 30, 2019, the minutes confirm that a single well-designed adequate and well-controlled Phase III clinical trial demonstrating safety and efficacy of iclaprim in patients with HABP, including VABP, along with data on potential mechanisms of hepatic injury, would enable submission of a New Drug Application for approval by FDA. It would take several years to enroll and complete a HABP/VABP Phase III trial and the cost is expected to be tens of millions of dollars.
The Company continues to believe that the most efficient way to generate future value from iclaprim is for a partner or other entity with a lower cost of capital to complete the HABP/VABP Phase III trial and commercialise the asset globally.
Sensyne Health (SENS) 107.5p £135m
Sensyne Health, the British clinical AI technology company, today announced it has joined Bayer’s LifeHub UK in an extension of its existing collaboration with Bayer to accelerate the development of new treatments using clinical artificial intelligence. Sensyne Health will work in partnership with Bayer on novel projects at the LifeHub UK including its inaugural project – the development of AI-enabled radiology to enhance patient outcomes.
LifeHub UK, which launches today, forms part of a global network of Bayer innovation hubs. The LifeHub UK is designed to accelerate and optimise disease detection and data-driven drug discovery by enabling Artificial Intelligence (AI)-enabled imaging solutions. Sensyne Health will be one of the first companies to have a presence in the LifeHub.
Avacta Group (AVCT) 19.5p £23m
Avacta Group, a biotechnology company developing novel cancer immunotherapies based on its proprietary Affimer® platform, today announces that it has entered a collaboration and option agreement with ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody-drug conjugates for patients suffering from haematological malignancies and solid tumors. The agreement is to develop Affimer-drug conjugates combining Avacta’s Affimer® technology with ADC Therapeutics’ pyrrolobenzodiazepine (PBD)-based warhead and linker technologies.
Tekmar Group (TGP) 145p £72m
Tekmar, a market-leading technology provider of subsea protection systems announced that it has today signed a sale and purchase agreement for the acquisition of Pipeshield for a consideration of £6.5m from its founder Steven Howlett.
Pipeshield is a global market leader in the provision of patented subsea concrete mattress protection systems;
Revenue and profit before tax of £6.6m and £0.8m respectively in the year ended 31 December 2018 (“FY18”);
As at 31 August 2019, Pipeshield had net assets of c.£3.1m, including c.£1.1m cash, c.£3.0m trade debtors and c.£1.3m trade creditors;
Premier AM Group (PAM) 176.5p £187m
Premier Asset Management Group PL today announces a trading update for the Company’s fourth quarter ended 30 September 2019.
Assets under management (AUM) were £6.6 billion as at 30 September 2019 (30 September 2018: £6.9 billion)
Outflows for the quarter of £246m (3 months to 30 September 2018: inflows £120 m)
Total net outflows of £233m for the twelve months to 30 September 2019 (twelve months to 30 September 2018: inflows £734m)
The Company expects to announce its final audited results for the year ended 30 September 2019 on 28 November 2019
Recommended all-share merger with Miton Group plc approved by shareholders: expected effective date 14 November 2019
Caledonia Mining Crp (CMCL) 575p £61.8m
Caledonia Mining Corporation Plc announced the successful installation and commissioning of a new oxygen plant at the Blanket Mine in Zimbabwe.
The new oxygen plant is expected to improve metallurgical recovery and reduce cyanide consumption at Blanket. Based on test work conducted, it is anticipated that the plant will improve overall metallurgical recoveries at Blanket to approximately 94 per cent. Recoveries have averaged approximately 93 per cent in 2019.
John Lewis Of Hunger (JLH) 0.61p £1.12m
John Lewis of Hungerford, the specialist manufacturer and retailer of kitchens, bedrooms and freestanding furniture, provides an update to the market on its expected outturn for the year ended 30 June 2019 and current trading.
Further to the announcement on 7 May 2019, the Company confirms that trading in the second half of the year was better than anticipated then and, therefore, it now expects to report a loss in the range of £220,000 to £240,000 for the year ended 30 June 2019.
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.